Biomea Fusion Inc. (BMEA)
1.99
-0.14 (-6.57%)
At close: Apr 01, 2025, 3:59 PM
2.01
0.92%
After-hours: Apr 01, 2025, 06:40 PM EDT
-6.57% (1D)
| Bid | 1.99 |
| Market Cap | 72.12M |
| Revenue (ttm) | 6.15M |
| Net Income (ttm) | -144.08M |
| EPS (ttm) | -4.01 |
| PE Ratio (ttm) | -0.5 |
| Forward PE | -1.4 |
| Analyst | Buy |
| Ask | 2.34 |
| Volume | 1,154,325 |
| Avg. Volume (20D) | 643,850 |
| Open | 2.24 |
| Previous Close | 2.13 |
| Day's Range | 1.94 - 2.29 |
| 52-Week Range | 1.94 - 14.43 |
| Beta | -0.28 |
About BMEA
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redw...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 16, 2021
Employees 107
Stock Exchange NASDAQ
Ticker Symbol BMEA
Website https://biomeafusion.com
Analyst Forecast
According to 12 analyst ratings, the average rating for BMEA stock is "Buy." The 12-month stock price forecast is $22, which is an increase of 1005.53% from the latest price.
Stock Forecasts2 months ago
+2.3%
Biomea Fusion shares are trading higher after the ...
Unlock content with
Pro Subscription
3 months ago
-20.68%
Biomea Fusion shares are trading lower. The company reported Phase II results for Icovamenib in Type 2 diabetes.
